MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ
4.410
-0.020
-0.45%
Closed 19:37 12/04 EST
OPEN
4.420
PREV CLOSE
4.430
HIGH
4.465
LOW
4.310
VOLUME
808.84K
TURNOVER
0
52 WEEK HIGH
5.10
52 WEEK LOW
2.705
MARKET CAP
848.15M
P/E (TTM)
-19.8649
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ABUS last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at ABUS last week (1117-1121)?
Weekly Report · 11/24 10:22
Arbutus Biopharma Reports Q3 2025 Financial Results
TipRanks · 11/19 03:52
Weekly Report: what happened at ABUS last week (1110-1114)?
Weekly Report · 11/17 10:22
Chardan Capital Maintains Arbutus Biopharma (ABUS) Buy Recommendation
NASDAQ · 11/15 12:03
Arbutus Biopharma Is Maintained at Buy by Chardan Capital
Dow Jones · 11/14 21:07
Arbutus Biopharma Price Target Maintained With a $5.00/Share by Chardan Capital
Dow Jones · 11/14 21:07
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Benzinga · 11/14 20:56
More
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Webull offers Arbutus Biopharma Corp stock information, including NASDAQ: ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.